KYNTRA BIO, INC.: basic earnings per share

What this measure means

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Diluted earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

The 2021 and 2022 figures for Kyntra Bio come from the historical FibroGen filing. It excludes potential shares because the company reported losses in those periods. Shares are displayed in thousands with inline scale 3; full counts and USD EPS are retained as reported in that filing. These older values have not been rescaled to the later 2025 reverse-split basis. Read the source filing.

Kyntra Bio, formerly FibroGen, reports positive total EPS of $45.37 in 2025, while continuing operations had a loss. Its dilution note explicitly bases the exclusion of potential shares on losses from continuing operations in 2024 and 2025; total profit does not establish dilution. Discontinued operations account for the positive 2025 total. This filing retrospectively adjusts share amounts for the June 16, 2025 one-for-25 reverse split and displays weighted-average shares in thousands with inline scale 3. Its 2024 and 2025 values are retained on that reported basis; older filing values are not silently rescaled. Read the source filing.

Selected filing history

Related financial histories

• KYNTRA BIO, INC.: total assets
• KYNTRA BIO, INC.: total liabilities
• KYNTRA BIO, INC.: stockholders equity
• KYNTRA BIO, INC.: cash and cash equivalents
• KYNTRA BIO, INC.: net income or loss
• KYNTRA BIO, INC.: operating cash flow
• KYNTRA BIO, INC.: capital expenditure payments
• KYNTRA BIO, INC.: revenue
• KYNTRA BIO, INC.: contract revenue excluding tax
• KYNTRA BIO, INC.: financing cash flow
• KYNTRA BIO, INC.: investing cash flow
• KYNTRA BIO, INC.: retained earnings or deficit
• KYNTRA BIO, INC.: basic weighted-average shares
• KYNTRA BIO, INC.: diluted weighted-average shares
• KYNTRA BIO, INC.: diluted earnings per share
• KYNTRA BIO, INC.: income tax expense or benefit
• KYNTRA BIO, INC.: net property, plant and equipment
• KYNTRA BIO, INC.: share-based compensation expense
• KYNTRA BIO, INC.: operating income or loss
• KYNTRA BIO, INC.: current assets
• KYNTRA BIO, INC.: interest expense
• KYNTRA BIO, INC.: current liabilities
• KYNTRA BIO, INC.: current accounts payable
• KYNTRA BIO, INC.: net current accounts receivable
• KYNTRA BIO, INC.: operating expenses
• KYNTRA BIO, INC.: net inventory
• KYNTRA BIO, INC.: cost of revenue
• KYNTRA BIO, INC.: selling, general and administrative expense
• KYNTRA BIO, INC.: research and development expense

Inspect the source

Entity

KYNTRA BIO, INC. / CIK 0000921299

Captured

2026-09-20T05:08:01.696Z

SEC response SHA-256

60313741a614d381e73fc033725566bd06ee27593e71b4e95a10100fd7a817db

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000921299.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))